title: Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a.
abstract: Ten patients suffering from discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) were treated with interferon alpha 2a. A marked improvement or clearing of cutaneous lupus erythematosus lesions was observed in eight of them. However, the response to interferon was of short duration and within a few weeks after interferon withdrawal all patients who were improved or cleared relapsed. This study suggests that interferon alpha 2a represents a new interesting approach in the treatment of DLE and SCLE. Ongoing trials will define the optimal treatment schedule for the maintenance of interferon-induced improvement of cutaneous lupus erythematosus.
authors: Clinique Dermatologique, Lyon, France.
authors: J F
authors: JF
authors: Nicolas
authors: J
authors: J
authors: Thivolet
authors: J
authors: J
authors: Kanitakis
authors: S
authors: S
authors: Lyonnet
mesh_terms: D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins